Background-Prior estimates of lifetime risk (LTR) for cardiovascular disease (CVD) examined the impact of blood pressure (BP) at the index age and did not account for changes in BP over time. We examined how changes in BP during middle age affect LTR for CVD, coronary heart disease, and stroke. Methods and Results-Data from 7 diverse US cohort studies were pooled. Remaining LTRs for CVD, coronary heart disease, and stroke were estimated for white and black men and women with death free of CVD as a competing event. LTRs for CVD by BP strata and by changes in BP over an average of 14 years were estimated. Starting at 55 years of age, we followed up 61 585 men and women for 700 000 person-years. LTR for CVD was 52.5% (95% confidence interval, 51.3-53.7) for men and 39.9% (95% confidence interval, 38.7-41.0) for women. LTR for CVD was higher for blacks and increased with increasing BP at index age. Individuals who maintained or decreased their BP to normal levels had the lowest remaining LTR for CVD, 22% to 41%, compared with individuals who had or developed hypertension by 55 years of age, 42% to 69%, suggesting a dose-response effect for the length of time at high BP levels. Conclusions-Individuals who experience increases or decreases in BP in middle age have associated higher and lower remaining LTR for CVD. Prevention efforts should continue to emphasize the importance of lowering BP and avoiding or delaying the incidence of hypertension to reduce the LTR for CVD. (Circulation. 2012;125:37-44.) (J.D.B.) . The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
C ardiovascular disease (CVD) is responsible for more than one third of all deaths in the United States. 1 Although CVD mortality rates have decreased over the past 4 decades, it remains the leading cause of death and one of the top causes of functional disability. 1 Given the burden of CVD, further efforts are needed to improve CVD prevention. Clinical practice guidelines focused on prevention have recommended developing lifetime risk (LTR) estimates as a method for improved long-term prediction for individuals, better estimation of the burden in the population, and more appropriate comparisons of risk between diseases. 2, 3 In addition, LTR estimates appear to be particularly useful in education campaigns because they may be more easily understood than traditional epidemiological measures. 3, 4 Clinical Perspective on p 44
The LTR for CVD among whites has been estimated to be 1 in 2 for men and 1 in 3 for women. 5 Data from a single cohort with a limited number of blacks suggest that black men and women have LTRs for CVD death at least as high as those for whites of the same sex. 6 In addition, the LTR for CVD increases with increasing risk factor burden. 6, 7 Blood pressure (BP) represents one of the most important modifiable risk factors for CVD. The LTR for CVD, particularly stroke, increases dramatically with increasing BP for both blacks and whites such that the remaining LTR for CVD was twice as high among individuals with stage 2 hypertension in middle age compared with those with optimal BP levels. 7 Previous studies of the LTR for CVD have been limited to single measures of BP during middle age. 8 However, to be more useful for individualized risk prediction and communication, detailed, risk factor-specific LTR estimates must be developed. 4 Systolic BP generally increases linearly with age, and individuals with higher systolic BP experience the largest increases. 9 However, little is known about how changes in BP during middle age may affect the LTR for CVD. Accordingly, we examined the impact of BP at specific ages and BP change over Ͼ10 years on the LTR for all CVD and for fatal and nonfatal coronary heart disease (CHD) and stroke among black and white men and women in the Lifetime Risk Pooling Project.
Methods

Study Sample
Data for this study came from the Cardiovascular Lifetime Risk Pooling Project. Detailed methods for the Pooling Project have previously been published. 7 In brief, data from 17 US epidemiological cohort studies were pooled to create the Cardiovascular Lifetime Risk Pooling Project. All cohorts had to meet several criteria: (1) community-or population-based sampling or large volunteer cohort;
(2) availability of at least 1 baseline examination at which participants provided demographic, personal, and medical history information and underwent direct measurement of physiological or anthropometric variables (eg, BP, weight); (3) longitudinal follow-up of at least 10 years with complete or near-complete ascertainment of vital status; and (4) availability of cause-specific or cardiovascular mortality data with or without ascertainment of nonfatal cardiovascular events. Because one of the chief aims of the Cardiovascular Lifetime Risk Pooling Project is to compare LTRs between different race/ethnic groups, we specifically sought to obtain data from cohort studies that included nonwhite race/ethnic groups. We did not include cohorts of individuals that participated in clinical trials, had only self-report of risk factors for important covariates without direct physical examination by study investigators, or had few deaths or events.
Data sets that included all cardiovascular outcomes, including fatal and nonfatal stroke, were included in this study. 11 FOS, 12 and HHP. 13, 14 Data from the Kaiser Permanente Study of the Oldest Old 15 were obtained from the Inter-University Consortium for Political and Social Research at the University of Michigan (http://www.icpsr.umich.edu/ICPSR/index.html). Complete data sets were obtained directly by agreement from the CHS 16 and WHI Observational Study 17 investigators. After all of the data were obtained, variables of interest from each data set were cleaned and renamed with the use of a standardized protocol to allow ease of use in the pooling project analyses. Given that data were obtained from cohort studies spanning 6 decades from the 1940s to the 2000s, there were differences between studies in measurement techniques. Whenever possible, values obtained with the most similar techniques were used for analyses. All data were appropriately deidentified, and all study protocols and procedures were approved by the IRB at Northwestern University.
BP Measures
For all cohorts except the Kaiser Permanente Study, BP was recorded as the average of 2 or 3 seated measurements taken by trained study personnel on manual mercury sphygmomanometers ( Table I in the online-only Data Supplement). BP data for participants of the Kaiser Permanente Study of the Oldest Old were taken from clinical measurements recorded in the participants' medical record. Participants were grouped according to their index BP as measured within 5 years of each index age. For example, BPs measured in individuals between 40 and 50 years of age were included in the analyses for the index age of 45 years. According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 18 criteria, the average of at least 2 BP measurements was categorized as follows: normal, Ͻ120/Ͻ80 mm Hg untreated; prehypertension, systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg untreated with medication; stage 1 hypertension, systolic BP of 140 to 159 mm Hg or diastolic BP of 90 to 99 mm Hg untreated with medication; and stage 2 or treated hypertension, systolic BP Ն160 mm Hg, diastolic BP Ն100 mm Hg, or treated with antihypertensive medication. The prevalence of hypertension treatment in this study is low because of the time period during which these cohorts were initiated. In addition, although the risk for CVD is reduced for hypertensive individuals who receive antihypertensive medication, their risk remains higher than that for individuals with untreated, ideal BP levels. 19 Therefore, to be conservative, we included treated individuals in the highest-risk group.
BP changes were examined among individuals who had at least 2 separate BP measurements Ն10 years apart. The baseline BP measurement had to have been after 20 years of age and at least 10 years before the BP measurement at the index age, as defined above. On average, baseline BP measurements were recorded 14 years before the index age; ie, on average, baseline BPs were taken at 41 years of age for the index age of 55 years. To classify an individual's change in BP, we collapsed BP into 3 categories: normal, Ͻ120/ Ͻ80 mm Hg untreated; prehypertension, untreated systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg; or hypertension, systolic BP Ն140 mm Hg, diastolic BP Ն90 mm Hg, or treated hypertension. BP change was categorized into 9 categories based on the change from the first to second measurement.
Event Ascertainment and Definition
For all cohorts except the Kaiser Permanente Study of the Oldest Old, CVD was defined as fatal CHD, hospitalized myocardial infarction, nonhospitalized myocardial infarction, and fatal and nonfatal stroke by trained physician-adjudicators using all available medical records. For death events, many cohorts used linkage to the National Death Index for underlying cause of death from death certificate data, whereas others used adjudicated cause of death by study investigators after review of all available medical records and/or autopsy data. For the present analyses, deaths resulting from CVD (as adjudicated or indicated by International Classification of Disease, 8th revision [ICD-8], ICD-9 codes 390 -458, and ICD-10 codes I00-I99) or CHD (as adjudicated or indicated by ICD-8 and ICD-9 codes 410 -414 and ICD-10 codes I20-I25) were included. Nonfatal events of interest, including myocardial infarction and stroke, were obtained only from studies that adjudicated events with 1 exception (the Kaiser Permanente Study). Criteria for adjudication of myocardial infarction and stroke have been published for these cohorts: ARIC, 10 CHS, 16 FHS and FOS, 5, 8 HHP, 20 and WHI. 17 Diagnosis of myocardial infarction generally required at least two of the following criteria for diagnosis: typical chest discomfort, evolution of ECG abnormalities consistent with myocardial infarction, and serological evidence of myocardial necrosis. For most cohorts, stroke was diagnosed as a persistent central neurological deficit(s) lasting Ͼ24 hours and unexplained by other causes, as adjudicated by trained physician adjudicators using standard criteria. 10 -17 In the Kaiser Permanente Study, 15 incident stroke events were ascertained from hospitalization discharge codes. For this cohort, we counted only the first hospitalization for which stroke (ICD-8 and ICD-9 codes 430 -438 and ICD-10 codes I60-I69) was the first-listed discharge diagnosis.
Statistical Analyses
LTR was calculated by a modified technique of survival analyses [21] [22] in which participants contribute information on the incidences of CVD, CHD, and stroke for each age they attain during follow-up. This approach has been used in numerous prior studies of LTR. [23] [24] Each subject in the study was followed up from study entry until the occurrence of a first CVD event, death, or age 95. Remaining LTR estimates for CVD, CHD, and stroke were stratified by BP level and were calculated separately for black and white men and women beginning at 45, 55, 65, and 75 years of age. LTR estimates for CVD, CHD, and stroke were also stratified by change in BP category for the index age of 55 years. Because of the limited number of blacks and overall similar patterns of association with BP, blacks and whites were combined in estimates of LTR by change in BP. LTRs to 85 years of age by strata of change in BP were estimated. Given the uncertainty associated with small numbers, LTR estimates are reported only when the adjusted person-time exceeded 100 person-years at the extremes of age. All statistical analyses were performed with SAS statistical software version 9.1 (SAS Institute, Inc, Cary, NC).
Results
Study Sample and Remaining LTR for CVD, CHD, and Stroke
A total of 61 585 men and women were followed up from 55 years of age and contributed 695 394 person-years of followup. The numbers of participants, events, and person-years of follow-up for stroke, CHD, and CVD at the index ages of 45, 55, 65, and 75 years are shown in Table II in the online-only Data Supplement. Given the large number of participants and years of follow-up at the index age of 55 years and the relatively few events that occurred before this age, we focused our findings on the remaining LTR starting at the index age of 55 years. Overall, starting at the age of 55 years, the remaining LTR for CVD was 52.5% ( 
Remaining LTR by BP at Index Age
When participants were categorized according to their BP at the index age of 55 years, 25.7% of men and 40.8% of women had normal BPs, 49.4% of men and 47.5% of women had prehypertension, 18.1% of men and 9.6% of women had stage 1 hypertension, and 6.8% of men and 2.2% of women had stage 2 or treated hypertension. The LTR for CVD, CHD, and stroke increased with increasing BP category for both men and women (Tables 1-3, the Figure, and Table IV in the online-only Data Supplement). LTR for CVD by BP was similar for the index age of 45 years ( Figure I in the online-only Data Supplement). As shown in Table 4 , the higher the BP level was, the younger the age was at which participants reached a LTR for CVD, CHD, and stroke of 8% (a measure of early burden and approximately half of the remaining LTR to 85 years of age). In general, black women had the greatest age difference (9 -21 years) between when the lowest and highest BP strata reached an LTR of 8%; the difference was largest for stroke. The age at which blacks reached a higher LTR was younger than for whites at almost all BP levels. These patterns were similar when cohorts were examined individually and when results were examined with and without the relatively large number of WHI participants ( Table IV in 
BP Changes During Middle Age
More than half of all men and women remained in consistent BP strata from 41 through 55 years of age (Table III in the online-only Data Supplement). Almost 20% of men experienced decreases in their BP and 30% experienced increases before 55 years of age. In contrast, almost 40% of women experienced an increase in BP and only 10% experienced a decrease before 55 years of age. At baseline, men tended to have higher systolic BPs; however, by the index age of 55 years, systolic BPs were higher among women owing to larger increases in BP observed among women during middle age. Individuals who became hypertensive during middle age experienced the largest increases in systolic BP with an increase of 32 mm Hg. Women had lower diastolic BPs in all categories. Changes in diastolic BP over middle age were similar for both men and women. Participants who experienced decreases in BP during middle age had smaller increases in total cholesterol and body mass index compared with participants who maintained their BP or experienced increasing BP. 
Change in BP and Remaining LTR for Stroke
Men and women who consistently had BPs Ͻ120/ Ͻ80 mm Hg and those whose BP decreased to Ͻ120/ Ͻ80 mm Hg over time tended to have the lowest remaining LTR for CVD, CHD, and stroke ( Table 5 ). The remaining LTRs were similar for individuals whose BP was consistently Ͻ120/Ͻ80 mm Hg and those whose BP decreased to this level. Individuals whose BP increased over time before 55 years of age had higher LTRs compared with those whose BP remained stable or decreased before 55 years of age. Although the findings were similar for men and women, men who had hypertension throughout middle life experienced the highest remaining LTR for stroke, whereas men whose BP increased to hypertensive levels had the highest LTRs for CVD and CHD. In contrast, women whose BP increased to hypertensive levels by 55 years of age had the highest LTR for stroke, but those who consistently had hypertensive levels before 55 years of age had the highest LTRs for CVD and CHD.
Discussion
Among the cohorts included in the Lifetime Risk Pooling Project, the remaining LTR for CVD was 52.5% in men and significantly lower LTRs for CVD, Ϸ35% to 40% and 22% to 25% for men and women, respectively. Among the white participants of the FHS (40 -59 years of age), previous estimates for the LTR of CVD, 51.7% for men and 39.2% for women, were similar to those in this study, 52.5% and 39.9%, respectively. 25 LTR estimates for CHD were lower in this study compared with previous estimates from the FHS, 30.9% versus 40.8% for men and 17.5% versus 24.6% in women. 5 Similarly, LTR estimates for stroke were slightly lower in this study compared with previous estimates from the FHS, 11.2% versus 14.5% for men and 14.7% versus 18.1% in women, although participants in the FHS were followed up to 106 years of age compared with 95 years of age in this study. 8 Birth-cohort effects may explain the lower LTRs for stroke observed in this study because FHS participants were recruited into the original FHS cohort in 1948 compared with some of the more contemporary cohorts included in the Lifetime Risk Pooling Project. Significant declines in BP levels have occurred over the past 50 years as a result of improvements in population levels of untreated BP and increased treatment and control of hypertension. 26 -28 Even within the FHS, Carandang et al 29 found a trend toward decreased LTR of stroke from 1950 to 2004. Although decreasing population BP levels may have resulted in slightly lower overall LTR estimates than those previously published by the FHS, analyses within the Lifetime Risk Pooling Project have demonstrated that, regardless of changes in prevalence, the association between BP and LTR for CVD remains the same over time within strata. 7 Prior estimates for the LTR for CVD have been based on single BP measurements taken at or near the index age. However, individuals are exposed to different BP levels throughout their life; thus, a more detailed examination of the effect of BP exposure is warranted. Systolic BP tends to increase linearly throughout middle age, although there is variability in the slope of the increase. 9 Individuals with the highest levels of systolic BP at baseline appear to have the largest age-related linear increases in systolic BP. 9 Above and beyond current BP, antecedent BP has been found to be an important determinant in risk for CVD. 30 Specifically examining stroke risk, studies done among Japanese populations have found that, in addition to current BP, BP increases over the prior 20 years represent an independent risk factor for stroke. 31 Individuals who were found to have hypertension at multiple time points had the greatest risk for stroke. 32 The present study is the first to examine how changes in BP throughout middle age (average change from 41 to 55 years of age) affect subsequent LTRs for CVD, CHD, and stroke among a large, diverse US population. We found that individuals who maintained or reduced their BP to normal levels by 55 years of age had the lowest LTRs. Decreases in BP may have been due to lifestyle changes, as suggested by the changes in body mass index and total cholesterol, although it is possible that differences were due to random variation or regression to the mean. The highest LTR for CVD among men was among those who developed hypertension during middle age. In contrast, among women, individuals who had hypertension from 41 through 55 years of age had the highest LTR for CVD. Although it was not consistently evident that a longer duration of high BP was associated with increased LTRs, it is possible that a greater duration of hypertension is associated with increased competing risk from non-CVD mortality.
Our findings suggest the hypothesis that there may be a dose-response effect for the length of time at higher BPs. Buck et al 33 found that the cardiovascular risk for hypertensive patients was highest for those who developed hypertension at younger ages and declined as age of onset increased from 40 to 69 years of age. Similarly, patterns in our findings suggest that women who had developed hypertension by early middle age (mean age, 41 years) had a higher LTR for CVD and CHD compared with those who had developed hypertension later in middle age, at 55 years of age. A similar pattern was seen among men when examining the remaining LTR of stroke.
This study has several strengths. First, we examined the LTR for CVD among a large, diverse sample of populationbased cohorts. These analyses included almost 700 000 person-years of follow-up. Many of the cohorts included in the Lifetime Risk Pooling Project are more contemporary than those used to derive prior estimates of the LTR for stroke, thereby providing more current LTR estimates. Importantly longitudinal BP measurements were available, allowing us to examine how BP changes over an average of 14 years during middle age affect the LTR for CVD. However, some individuals may not have had a second BP available because of death or, more likely, the cohort structure and timing of visits. These individuals therefore would not have been included in our analyses of BP change. Despite pooling, there was limited follow-up for blacks; therefore, we had to combine races in our analyses on change in BP and were unable to determine racial differences in the association between BP changes and LTR for CVD. By examining stratified estimates, we have adjusted for any confounding by age, race, sex, and BP; however, the methods used to determine LTR do not allow for adjustment, so there may be potential confounding by other factors such as socioeconomic status, body mass index, and other behavioral factors that could not be included in the model. In addition, we pooled multiple population-based cohorts, and there is a potential for heterogeneity resulting from birth-cohort effects and/or secular trends in the LTR estimates. Although there have been secular trends in the CVD event rates and treatment patterns, 29 most of the follow-up we have is before the widespread use of antihypertensives and lipid-lowering therapies. In the Lifetime Risk Pooling Project, the prevalence of risk factors has changed over birth cohorts; however, the relationships between risk factors and outcomes have remained remarkably consistent across cohorts and birth cohorts in the Lifetime Risk Pooling Project. In addition, changes in an individual's treatment status during follow-up may have affected that person's remaining LTR for CVD. However, the data we used to estimate LTRs for stroke are similar to what would be available to patients and clinicians at a given index age, without knowledge of subsequent changes in treatment strategy. Given the limited follow-up duration, it is not possible to estimate LTRs using only data from cohorts recruited in the last decade, when antihypertensive use has become prevalent.
Our results suggest that there may be a dose-response effect for the number of years with high BP on the LTR of CVD, CHD, and stroke. Individuals who are able to maintain or to decrease their BP to normal BP levels during middle age have the lowest LTR for CVD. In contrast, individuals who experience an increase in BP have higher LTRs for CVD. Taking BP changes into account can provide more accurate estimates for LTR for CVD and represent a step forward in developing individualized risk prediction strategies. Therefore, avoiding hypertension before middle age and delaying the onset of the development of hypertension both appear to have a significant impact on an individual's remaining LTR for CVD.
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